INGN 225

Thuốc Gốc

Biotech

INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.

Dược Lực Học : INGN 225 uses the p53 tumor suppressor in a different manner than ADVEXIN to create a molecular immunotherapy for cancer that stimulates a particular type of immune system cell known as a dendritic cell. Testing has shown that the human immune system can recognize and kill tumors after treatment with dendritic cells stimulated by the p53 tumor suppressor, which suggests this therapy could have broad utility as a treatment for solid tumors. INGN 225 may also sensitize tumors to the effects of platinum and taxane chemotherapies.

Chỉ Định : Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB05325

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading